一个用oclacitinib治疗的狗的语言淋巴瘤病例
Shohei Nishimori1, Kumiko Okano2, Kazumi Nibe3
1Jiyugaoka Animal Clinic, Tokyo, Japan.
The Journal of veterinary medical science
|April 6, 2025
概括
一只玩具柴犬的罕见犬舌性T区淋巴瘤 (TZL) 病例显示,使用oclacitinib有所改善. 这种治疗方法,通常用于亚托皮性皮炎,为狗TZL提供了一种新的方法,没有传统化疗.
科学领域:
- 兽医瘤学 兽医瘤学
- 比较病理学比较病理学
背景情况:
- 舌头犬类T区淋巴瘤 (TZL) 是一种罕见的外节性犬类淋巴瘤.
- 早期诊断和治疗对于管理犬类淋巴瘤至关重要.
研究的目的:
- 在玩具狗狗中报告一例犬舌性TZL病例.
- 评估oclacitinib在治疗语言TZL.L.方面的疗效.
主要方法:
- 通过穿孔活检,组织病理学和免疫组织化学来诊断语言TZL.
- 用oclacitinib进行治疗,oclacitinib是一种被批准用于治疗犬类亚托皮炎的Janus激酶 (JAK) 抑制剂.
主要成果:
- 用oclacitinib.成功地管理了语言TZL病变.
- 在没有常规抗癌疗法的情况下观察到显著的改善.
结论:
- 奥克拉西替尼 (oclacitinib) 显示出作为犬类语言TZL有效治疗的潜力.
- 这一案例突出了这种罕见的狗癌症的新治疗策略.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


